Candel Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Candel is a clinical-stage biopharmaceutical company developing viral immunotherapies for cancer. It has no approved products and has generated no revenue from product sales.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $4.1 million | $5.5 million |
| General and administrative expense | $3.8 million | $4.2 million |
| Total operating expenses / operating loss | $7.9 million | $9.6 million |
| Net loss | $8.2 million; $0.28 per share | $8.8 million; $0.30 per share |
| Cash used in operating activities | $8.4 million | $10.8 million |
| Cash and cash equivalents at period-end | $25.7 million | Not stated here for the comparable date |
| Debt | $19.7 million carrying value, including term loan and other long-term debt | — |
Operating expenses declined by $1.7 million year over year, mainly reflecting lower employee-related costs after the late-2023 workforce reduction and lower clinical-development costs. Reduced interest income and a much smaller warrant fair-value gain partly offset the lower operating loss. Cash and cash equivalents fell from $35.4 million at December 31, 2023; financing cash use included $1.7 million of term-loan principal payments. Profit margins are not meaningful because the company has no product revenue.
At March 31, current assets were $27.1 million and current liabilities were $13.5 million. Stockholders’ equity was $6.0 million, down from $12.7 million at year-end 2023. The term loan matures January 1, 2026, bears a floating rate, and had a reported weighted-average effective interest rate of 11.40%.
Pipeline, outlook and management commentary
- Funding: Management expects existing cash and cash equivalents to fund the current operating plan into the fourth quarter of 2024. The filing states that substantial doubt exists about the company’s ability to continue as a going concern for the one-year period following issuance of the financial statements. Additional funding is required; no committed external funding source is identified.
- CAN-2409: The pivotal Phase 3 prostate cancer trial and Phase 2 active-surveillance prostate trial are enrolled; topline results were expected in Q4 2024. The pancreatic cancer Phase 2 trial had paused new enrollment pending additional funding. The company reported positive interim pancreatic data and FDA fast track and orphan drug designations. For NSCLC, it expected to present Cohort 2 topline overall-survival data in June 2024; previously reported survival findings were preliminary and not mature.
- CAN-3110: The recurrent high-grade glioma program includes an investigator-sponsored Phase 1b trial. The company reported that six patients had received repeat dosing in an extension arm, with favorable tolerability reported, and expected to present related data in June 2024. The FDA granted fast track designation in February 2024.
- Research: The company continues to develop candidates using its enLIGHTEN platform and collaborates with the University of Pennsylvania on viral immunotherapies intended to enhance CAR-T approaches in solid tumors.
- Restructuring: A workforce reduction of approximately 45% was implemented in December 2023 to focus resources on CAN-3110 and the enLIGHTEN platform. The plan was completed in Q1 2024 with final severance payments of $46,000.
- Capital access: The company had raised approximately $0.2 million net under its ATM program through March 31, 2024, with no additional sales reported through May 6. Its public float exceeded $75 million on April 4, 2024, ending its then-applicable “baby shelf” limitation.
Material risks, contingencies and unusual items
- Manufacturing and FDA matter: On March 15, 2024, the company notified former CEO and former Chief Scientific Officer Dr. Aguilar-Cordova of allegations that he instructed personnel to falsify CAN-2409 sterility-testing results submitted to the FDA and failed to implement a compliant stability-testing program. He denied the allegations on March 26. The company says it updated the stability program, submitted additional information and data to the FDA, and concluded that trial participants were not put at risk and clinical-data integrity was not affected. The company requested his resignation from the board.
- Clinical and regulatory uncertainty: Product candidates remain investigational; trial results, including preliminary and interim data, may change and do not assure approval. The FDA’s Special Protocol Assessment for the Phase 3 prostate study does not guarantee approval. Viral immunotherapy development, manufacturing, safety, enrollment and regulatory review carry substantial risks.
- Financing and dilution: The company expects continuing losses and negative operating cash flow. Failure to raise capital on acceptable terms could require delaying, reducing or eliminating trials and development work. Equity financing could dilute stockholders; debt or collaborations could impose restrictions or require relinquishing rights.
- Debt and other commitments: The SVB term loan is secured by substantially all company assets other than intellectual property, which is subject to a negative pledge. Scheduled principal repayments began in February 2024; a final payment fee also applies. The Periphagen note is due in November 2027.
- Legal matters: The company reported no litigation it considers probable to have a material adverse effect. A prior arbitration dispute with Periphagen was resolved by a June 2023 amendment without financial impact.
- Controls: Management concluded disclosure controls were effective at the reasonable-assurance level as of March 31, 2024; no material change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Whether the FDA raises questions or imposes requirements related to the CAN-2409 sterility and stability-testing allegations, and whether the company’s assessment of patient safety and data integrity is sustained.
- Actual timing and final results of the prostate, NSCLC, pancreatic and CAN-3110 studies, distinguishing prespecified endpoints and mature results from interim or preliminary findings.
- Whether Candel secures sufficient financing before its stated runway into Q4 2024 expires, and the resulting effect on trial enrollment, program priorities and shareholder dilution.
- Cash burn, loan principal and interest payments, and the company’s ability to meet obligations while maintaining its clinical programs.
- Whether manufacturing arrangements, clinical execution and regulatory interactions support continued development of its viral product candidates.